(SHL) Siemens Healthineers - Ratings and Ratios
Imaging Systems, Diagnostic Equipment, Cancer Care Tech, Therapy
SHL EPS (Earnings per Share)
SHL Revenue
Description: SHL Siemens Healthineers
Siemens Healthineers AG is a global healthcare company that develops, manufactures, and sells diagnostic and therapeutic products and services. The company operates through four main segments: Imaging, Diagnostics, Varian, and Advanced Therapies, offering a range of medical equipment and services, including MRI and CT scanners, in-vitro diagnostic products, cancer care technologies, and image-guided minimally invasive treatments.
Key Performance Indicators (KPIs) for Siemens Healthineers AG include revenue growth, which has been driven by the increasing demand for healthcare services and the companys expanding portfolio of innovative products. The companys return on equity (RoE) is 11.16%, indicating a relatively stable return on shareholder investment. Additionally, the companys forward price-to-earnings ratio (P/E Forward) is 18.38, suggesting that the stock may be undervalued relative to its expected earnings growth.
The companys diversified product portfolio and global presence provide a solid foundation for long-term growth. Siemens Healthineers AG has a strong presence in the healthcare equipment industry, with a market capitalization of 52.634 billion EUR. The companys commitment to innovation and customer service is reflected in its comprehensive range of technical customer services, including maintenance, repair, and training.
From a valuation perspective, Siemens Healthineers AGs price-to-earnings ratio (P/E) is 25.23, which is relatively high compared to some of its peers. However, this may be justified by the companys strong brand reputation, diversified product portfolio, and growth prospects. Further analysis of the companys financial statements and industry trends is necessary to determine the stocks potential for long-term growth.
SHL Stock Overview
| Market Cap in USD | 62,627m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
SHL Stock Ratings
| Growth Rating | -6.62% |
| Fundamental | 70.2% |
| Dividend Rating | 53.2% |
| Return 12m vs S&P 500 | -17.2% |
| Analyst Rating | - |
SHL Dividends
| Dividend Yield 12m | 1.96% |
| Yield on Cost 5y | 2.72% |
| Annual Growth 5y | 3.50% |
| Payout Consistency | 98.6% |
| Payout Ratio | 42.0% |
SHL Growth Ratios
| Growth Correlation 3m | 38.8% |
| Growth Correlation 12m | -58.9% |
| Growth Correlation 5y | 24% |
| CAGR 5y | 3.56% |
| CAGR/Max DD 3y | 0.14 |
| CAGR/Mean DD 3y | 0.40 |
| Sharpe Ratio 12m | -0.55 |
| Alpha | -22.10 |
| Beta | 0.988 |
| Volatility | 21.61% |
| Current Volume | 456.3k |
| Average Volume 20d | 523k |
| Stop Loss | 46.3 (-3.2%) |
| Signal | -0.21 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (2.17b TTM) > 0 and > 6% of Revenue (6% = 1.40b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 3.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6.39% (prev 13.67%; Δ -7.28pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 3.39b > Net Income 2.17b (YES >=105%, WARN >=100%) |
| Net Debt (13.32b) to EBITDA (4.68b) ratio: 2.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.13b) change vs 12m ago 0.71% (target <= -2.0% for YES) |
| Gross Margin 38.76% (prev 37.82%; Δ 0.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.26% (prev 47.38%; Δ 3.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.39 (EBITDA TTM 4.68b / Interest Expense TTM 458.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.01
| (A) 0.03 = (Total Current Assets 14.13b - Total Current Liabilities 12.64b) / Total Assets 44.60b |
| (B) 0.06 = Retained Earnings (Balance) 2.70b / Total Assets 44.60b |
| (C) 0.07 = EBIT TTM 3.39b / Avg Total Assets 45.61b |
| (D) 0.08 = Book Value of Equity 2.28b / Total Liabilities 26.88b |
| Total Rating: 1.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.22
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 3.93% = 1.96 |
| 3. FCF Margin 11.21% = 2.80 |
| 4. Debt/Equity 0.89 = 2.12 |
| 5. Debt/Ebitda 3.35 = -2.18 |
| 6. ROIC - WACC 6.55% = 8.18 |
| 7. RoE 11.69% = 0.97 |
| 8. Rev. Trend 28.71% = 2.15 |
| 9. EPS Trend 24.06% = 1.20 |
What is the price of SHL shares?
Over the past week, the price has changed by +0.57%, over one month by +1.57%, over three months by +3.84% and over the past year by -1.60%.
Is Siemens Healthineers a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SHL is around 44.34 EUR . This means that SHL is currently overvalued and has a potential downside of -7.26%.
Is SHL a buy, sell or hold?
What are the forecasts/targets for the SHL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 60.2 | 25.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 49 | 2.6% |
SHL Fundamental Data Overview
Market Cap EUR = 53.41b (53.41b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 2.37b EUR (last quarter)
P/E Trailing = 24.6736
P/E Forward = 17.5747
P/S = 2.2842
P/B = 3.0455
P/EG = 1.5984
Beta = 0.746
Revenue TTM = 23.38b EUR
EBIT TTM = 3.39b EUR
EBITDA TTM = 4.68b EUR
Long Term Debt = 11.65b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.05b EUR (from shortTermDebt, last quarter)
Debt = 15.70b EUR (Calculated: Short Term 4.05b + Long Term 11.65b)
Net Debt = 13.32b EUR (from netDebt column, last quarter)
Enterprise Value = 66.73b EUR (53.41b + Debt 15.70b - CCE 2.37b)
Interest Coverage Ratio = 7.39 (Ebit TTM 3.39b / Interest Expense TTM 458.0m)
FCF Yield = 3.93% (FCF TTM 2.62b / Enterprise Value 66.73b)
FCF Margin = 11.21% (FCF TTM 2.62b / Revenue TTM 23.38b)
Net Margin = 9.29% (Net Income TTM 2.17b / Revenue TTM 23.38b)
Gross Margin = 38.76% ((Revenue TTM 23.38b - Cost of Revenue TTM 14.32b) / Revenue TTM)
Tobins Q-Ratio = 29.23 (Enterprise Value 66.73b / Book Value Of Equity 2.28b)
Interest Expense / Debt = 0.66% (Interest Expense 104.0m / Debt 15.70b)
Taxrate = 22.35% (564.0m / 2.52b)
NOPAT = 2.63b (EBIT 3.39b * (1 - 22.35%))
Current Ratio = 1.12 (Total Current Assets 14.13b / Total Current Liabilities 12.64b)
Debt / Equity = 0.89 (Debt 15.70b / last Quarter total Stockholder Equity 17.68b)
Debt / EBITDA = 3.35 (Net Debt 13.32b / EBITDA 4.68b)
Debt / FCF = 5.99 (Debt 15.70b / FCF TTM 2.62b)
Total Stockholder Equity = 18.58b (last 4 quarters mean)
RoA = 4.87% (Net Income 2.17b, Total Assets 44.60b )
RoE = 11.69% (Net Income TTM 2.17b / Total Stockholder Equity 18.58b)
RoCE = 11.20% (Ebit 3.39b / (Equity 18.58b + L.T.Debt 11.65b))
RoIC = 14.13% (NOPAT 2.63b / Invested Capital 18.61b)
WACC = 7.58% (E(53.41b)/V(69.11b) * Re(9.66%)) + (D(15.70b)/V(69.11b) * Rd(0.66%) * (1-Tc(0.22)))
Shares Correlation 3-Years: 9.38 | Cagr: -0.06%
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 73.95% ; FCFE base≈2.05b ; Y1≈2.22b ; Y5≈2.77b
Fair Price DCF = 32.59 (DCF Value 36.56b / Shares Outstanding 1.12b; 5y FCF grow 9.52% → 3.0% )
EPS Correlation: 24.06 | EPS CAGR: -0.56% | SUE: 2.52 | # QB: True
Revenue Correlation: 28.71 | Revenue CAGR: -2.09%